Stent Thrombosis Eight Years Past Drug-Eluting Stent Placement – A Case Report

Ana Baptista¹, Catarina Ferreira¹, Pedro Mateus¹, Henrique Carvalho², Ilídio Moreira¹
Centro Hospitalar de Trás-os-Montes e Alto Douro - Unidade de Vila Real; Centro Hospitalar do Porto - Hospital de Santo António; Instituto de Ciências Biomédicas de Abel Salazar - Universidade do Porto

Introduction

Stent thrombosis (ST) is a major concern in the drug-eluting stents (DES) era. There are several reports of stent thrombosis occurring up to five years after stent implantation. We report the case of a sixty eight-year-old woman with very late ST presenting as acute ST-elevation myocardial infarction (STEMI) after stopping antplatelet therapy eight years past DES placement. The long time-to-event of this case brings new questions to the controversial aspects of optimal follow-up time and the safety of antplatelet therapy cessation after recommended times are met in patients with DES.

Case Report

We present the case of a sixty eight-year-old woman with a history of multiple cardiovascular risk factors (diabetes, hypertension and hyperlipidemia) and a previous acute coronary syndrome (ACS) in 2003. At that time the coronary angiogram revealed total occlusion of the left anterior descending artery (LAD), long sub-occlusive stenosis of the left circumflex artery (LCX) and irregularities of the right coronary artery. Two sirolimus-eluting stents (2,5*28mm and 2,25*28mm) were implanted in the LAD and another two (2,25*28mm and 2,25*13mm) in the LCX, with a final Thrombolysis in Myocardial Infarction (TIMI) flow grade of III. The echocardiogram showed akinetic apical segment and preserved left ventricle function.

During the follow-up (2008) aspirin was changed to clopidogrel due to gastrointestinal side effects. She was on clopidogrel in addition to rosuvastatin, lisinopril, carvedilol and oral antidiabetics since then and remained asymptomatic until December 2010 when she described effort-related chest pain. A treadmill exercise stress test was performed and no ST-segment changes were observed but the patient referred chest pain at the peak of stress test. A myocardial perfusion scintigraphy showed normal left ventricle function (ejection fraction of 57%) and an extensive anterior, septal and apical scintigraphy showed normal left ventricle function (ejection fraction of 57%) and an extensive anterior, septal and apical ST-segment changes were observed but the patient referred chest pain. A treadmill exercise stress test was performed and no ST-segment changes were observed but the patient referred chest pain. A myocardial perfusion scintigraphy showed normal left ventricle function (ejection fraction of 57%) and an extensive anterior, septal and apical

Discussion

Coronary artery stents are widely used in patients undergoing PCI. DES dramatically reduce restenosis rates with a significant reduction of repeat revascularizations, when compared to bare-metal stents (BMS)¹. However, ST is a major concern, as the clinical consequences of ST are generally catastrophic, almost always presenting as death or large non-fatal myocardial infarction, usually with ST-segment elevation². Most cases of ST occur within the first thirty days after stent placement, but the risk is continuous at a rate of 0,6% per year for at least four years after stenting³. The longest time-to-ST case reports the authors found happened four to five years after stent deployment⁴. Recently the results of the DESERT registry were presented. It included 922 patients from more than 40 clinical centers who implanted first-generation DES, mainly Cypher and Taxus stents and experienced definite late or very late ST. The majority of the late ST occurred after 1 year (75%) and continued to occur up to 7.3 years⁵, extending the risk period even further. Our case report has twice the time-to-event of the other cases, and presented even later than the 7.3 years of the largest registry of DES thrombosis (DESERT), making the optimal follow-up duration of patients with DES stents even more uncertain.

The main pathologic mechanism of ST is delayed arterial healing characterized by incomplete endothelialization as showed by analysis of 40 consecutive autopsies of patients

Keywords

Myocardial Infarction; Drug-Eluting Stents; Thrombosis.

Mailing Address: Ana Baptista • Avenida da Noruega, Vila Real, 5000, Vila Real
E-mail: baptista_an@hotmail.com
Manuscript received June 06, 2012, revised manuscript October 22, 2012, accepted October 29, 2012.

DOI: 10.5935/abc.20130095
with stents – complete endothelialization of BMS occurred by six to seven months, whereas incomplete endothelialization persisted in the DES group beyond forty months\(^7\). Emerging evidence suggests in-stent neoatherosclerosis as another important substrate for late ST\(^8\). Although the precise mechanisms of neoatherosclerotic development remain unknown, the incidence of neoatherosclerosis is greater in DES lesions (31% vs 16% in BMS) and occurs earlier (420 days [361 to 683 days] vs. 2,160 days [1,800 to 2,880 days])\(^8\). Neoatherosclerosis is a probable explanation for ST during the first years after DES placement, but probably a less important mechanism for this case report with a much longer time-to-event. There are other risk factors concurring to ST including procedural aspects such as bifurcation stenting and incomplete stent apposition (ISA). ISA is defined as the absence of stent strut contact with the underlying vessel wall (not overlying a side branch). Late acquired ISA has been observed in 7% to 21% of DES\(^9\) and positive arterial remodeling with an increase of the external elastic membrane out of proportion to changes in plaque and media appears to be its most likely mechanism\(^9\). This patient had two 2,25*28mm stents in the LAD which may correspond to undersized stents. DES implantation occurred in context of ACS following a thrombotic occlusion of the LAD, the decrease of plaque with dissolution of jailed thrombus may have limited the stent size choice, with later influence in the occurrence of ISA. Also, withdrawal of antiplatelet therapy seems to be an important risk factor for ST. The median
time from dual antiplatelet therapy cessation to a thrombosis-related clinical event is seven days (with a range of 3 to 150 days)\(^4\). In clinical practice it isn’t unusual to have to consider antiplatelet therapy cessation due to, for example, surgery or gastrointestinal bleeding. In this case report the patient was on single antiplatelet therapy until the event occurred five days after she voluntarily stopped medication even eight years after stent implantation. This raises questions about the safety of discontinuation of therapy even after the recommended times are met.

**Conclusion**

Our case report draws the attention to the serious clinical implications of ST, highlighting the need to consider its possibility many years after stent implantation. As one of the longest reported time-to-event case it shows how the potential risk of ST should always be considered when antiplatelet therapy cessation is contemplated in patients with DES.

**References**


**Author contributions**

Acquisition of data: Baptista A, Ferreira C; Analysis and interpretation of the data and Critical revision of the manuscript for intellectual content: Baptista A, Ferreira C, Mateus P; Obtaining funding: Carvalho H; Writing of the manuscript: Baptista A.

**Potential Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**Sources of Funding**

There were no external funding sources for this study.

**Study Association**

This study is not associated with any post-graduation program.